
Join to view full profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-228-1000
Dr. Carpenter is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Sydney Faculty of MedicineClass of 1988
Certifications & Licensure
WA State Medical License 2001 - 2027
AK State Medical License 2022 - 2026
Publications & Presentations
PubMed
- Prospective phase 2 trial of high- and intermediate-intensity myeloablative conditioning for cord blood transplantation.John N Colgan, Theodore A Gooley, Jenna B Pedersen, Brandon Hadland, Corinne Summers
Blood Advances. 2026-10-21 - 1 citationsChronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development.Joseph Pidala, Betty K Hamilton, George L Chen, Lynn Onstad, Steven Z Pavletic
Blood Advances. 2026-10-13 - Interpreting pulmonary function tests in allogeneic hematopoietic cell transplant recipients.Nicola Alexandra Adderley, Jane Turner, Paul A Carpenter, Guang-Shing Cheng
Blood Advances. 2026-10-07
Press Mentions
- FDA Approves Ibrutinib (Imbruvica) for Graft-Versus-Host Disease in Children, Young AdultsAugust 25th, 2022
- (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host DiseaseAugust 24th, 2022
- The U.S. Food and Drug Administration Approved the Use of IMBRUVICA for the Treatment of Pediatric Patients One Year and Older with cGVHD After Failure of One or More Lines of Systemic TherapyAugust 24th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: